In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

Pooled data from 3 phase III clinical trial shows that the addition of neoadjuvant carboplatin to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer.

Adding tucatinib to first-line maintenance therapy with trastuzumab/pertuzumab extends PFS for patients with previously-treated HER2+ metastatic breast cancer.

Investigators sought to identify a relationship between cruciferous vegetable intake and breast cancer risk in the Nurses’ Health Study (NHS) and NHSII.

In patients with triple-negative breast cancer who have received neoadjuvant chemotherapy, testing for Ki67 and TILs has prognostic value.

Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.

In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.

Removing etoposide did not negatively affect OS, DFS, MRD, or relapse rate at 3 years for pediatric patients with LR1, LR2 or high-risk AML.

A treatment strategy of targeted therapy first allowed more than half of patients with newly diagnosed DLBCL to achieve a CR without chemotherapy.

Many families with children being treated for acute lymphoblastic leukemia face household material hardship and/or income loss.

Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.